Please use this identifier to cite or link to this item:
|Kruppel-Like Factor 15 Is Critical for the Development of Left Ventricular Hypertrophy.
|Patel, Sheila K ;Ramchand, Jay ;Crocitti, Vincenzo;Burrell, Louise M
|Medicine (University of Melbourne)
|International Journal of Molecular Sciences 2018; 19(5): E1303
|Left ventricular hypertrophy (LVH) is an independent risk factor for adverse cardiovascular events and is often present in patients with hypertension. Treatment to reduce blood pressure and regress LVH is key to improving health outcomes, but currently available drugs have only modest cardioprotective effects. Improved understanding of the molecular mechanisms involved in the development of LVH may lead to new therapeutic targets in the future. There is now compelling evidence that the transcription factor Kruppel-like factor 15 (KLF15) is an important negative regulator of cardiac hypertrophy in both experimental models and in man. Studies have reported that loss or suppression of KLF15 contributes to LVH, through lack of inhibition of pro-hypertrophic transcription factors and stimulation of trophic and fibrotic signaling pathways. This review provides a summary of the experimental and human studies that have investigated the role of KLF15 in the development of cardiac hypertrophy. It also discusses our recent paper that described the contribution of genetic variants in KLF15 to the development of LVH and heart failure in high-risk patients.
|International Journal of Molecular Sciences
|Kruppel-like factor 15
genetics of left ventricular hypertrophy
left ventricular hypertrophy
|Appears in Collections:
Show full item record
checked on Feb 25, 2024
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.